Related Experiment Videos
Immune Checkpoint Inhibitors for Brain Metastases
Aaron C Tan1, Amy B Heimberger2, Alexander M Menzies1,3,4
1Royal North Shore Hospital, St Leonards, NSW, Australia.
Current Oncology Reports
|April 19, 2017
Summary
Brain metastases have a poor prognosis. Immune checkpoint inhibitors show promise for improving outcomes, with ongoing trials to determine optimal use alongside existing therapies.
Area of Science:
- Oncology
- Neuro-oncology
- Immunotherapy
Background:
- Brain metastases are associated with poor prognosis and significant treatment-related morbidity.
- Current treatment involves surgery, radiation, chemotherapy, and immunotherapy.
- Understanding the role of immune checkpoint inhibitors (ICIs) in brain metastases is crucial.
Purpose of the Study:
- To evaluate the effectiveness of immune checkpoint inhibitors in managing brain metastases.
- To explore the potential of ICIs to improve outcomes for patients with brain metastases.
Main Methods:
- Review of retrospective analyses, particularly for melanoma metastases treated with ipilimumab.
- Ongoing prospective clinical trials investigating more active ICI agents.
Main Results:
- Existing evidence for ICIs in brain metastases is primarily from retrospective melanoma studies.
- Preliminary results from ongoing trials suggest potential activity of ICIs.
- ICIs hold promise for enhancing outcomes in patients with brain metastases.
Conclusions:
- Immune checkpoint inhibitors represent a potential advancement in treating brain metastases.
- Results from current clinical trials are essential for defining optimal treatment strategies.
- Future research will guide the integration of ICIs with local and systemic therapies.